A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma

INTRODUCTION: Afatinib is an ErbB family receptor inhibitor with efficacy in head and neck squamous cell carcinoma (HNSCC). A phase I trial was conducted to determine the maximally tolerated dose (MTD) of afatinib in combination with carboplatin and paclitaxel as induction chemotherapy (IC). MATERIA...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oral Oncol
Glavni autori: Chung, Christine H., Rudek, Michelle A., Kang, Hyunseok, Marur, Shanthi, John, Pritish, Tsottles, Nancy, Bonerigo, Sarah, Veasey, Andy, Kiess, Ana, Quon, Harry, Cmelak, Anthony, Murphy, Barbara A., Gilbert, Jill
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4707116/
https://ncbi.nlm.nih.gov/pubmed/26705063
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oraloncology.2015.11.020
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items